<DOC>
	<DOCNO>NCT00847106</DOCNO>
	<brief_summary>Dendritic cell ( DC ) professional antigen present cell immune system . Multiple distinct DC lineage 's exist well appreciate DC subset maturation stage DC determine type immune response , range TH1 TH2 response immune tolerance . The extremely potent capacity mature DC initiate immune response exploit fight infectious disease cancer . Others currently use tumor antigen load mature DC clinical vaccination study cancer , clinical well immunological response observe . Exciting new insight accompany revival suppressor T cell , refer regulatory T cell ( Treg ) , implicate also Treg play key role control immunity . Treg constitute sub-population CD4+ T cell constitutively express IL-2R alpha-chain ( CD25 ) . Treg show remarkably suppressive activity different component immune system , include T lymphocytes dendritic cell , suggest act initiation phase ( DC ) effector phase ( activate T cell ) immune response . Interestingly , temporal depletion Treg show enhance anti-tumor immune response case prolong absence Treg even autoimmunity . Furthermore , data mouse tumor model indicate temporal depletion Treg also result improve vaccine efficiency therapeutic setting , e.g . mice pre-existing tumor . These data imply tumor bearing patient depletion Treg prior vaccination improve vaccine efficacy . In study investigate effect regulatory T cell ( Treg ) depletion efficacy DC-based anti-tumor vaccine clinical study use melanoma associate antigens tyrosinase gp100-loaded DC deplete anti-CD25 mononuclear antibody ( Daclizumab ) . Our primary objective study induction effective anti-tumor immune response . Our secondary objective induction clinical response .</brief_summary>
	<brief_title>Augmentation Dendritic Cell-Based Vaccines Melanoma Patients Depletion Regulatory T Cells Stage IV Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Histologically documented evidence melanoma . 2 . Stage IV melanoma accord 2001 AJCC criterion . [ 53 ] Limited tumor burden ; LDH &lt; 2x upper limit normal . 3 . HLAA2.1 phenotype accord lymphocyte HLA typing . 4 . Expression gp100 and/or tyrosinase melanoma cell , detect immunohistochemistry , preferably metastatic tumor , available primary tumor . 5 . ECOG performance status 01 , life expectancy &gt; 3 month . 6 . Age 1875 year . 7 . Written informed consent . 8 . Expected adequacy followup . 9 . WBC &gt; 3.0 x 109/l , lymphocytes &gt; 0.8 x 109/l , platelet &gt; 100 x 109/l , serum creatinine &lt; 150 μmol/l , serum bilirubin &lt; 25 μmol/l . 10 . No clinical sign CNS metastasis , patient clinical suspicion CNS metastases CT scan brain perform exclude . 11 . No prior chemotherapy , immunotherapy , radiotherapy within three month plan vaccination allow . 12 . No previous treatment monoclonal antibody . 13 . No concomitant use corticosteroid immunosuppressive agent . 14 . No history second malignancy within last 5 year . Adequately treat basal carcinoma skin carcinoma situ cervix acceptable within period . 15 . No serious concomitant disease , active infection . Specifically , patient autoimmune disease organ allograft , HBsAg HIV positive patient exclude . 16 . Patients know allergy shell fish ( contains KLH ) exclude . 17 . Patients asthma severe allergic disease necessitate medication exclude 18 . No pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Dendritic Cells</keyword>
	<keyword>Regulatory T cell</keyword>
	<keyword>CD25</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>Stage IV Melanoma</keyword>
</DOC>